ClinicalTrials.gg
CompletedNCT03134222Updated Jun 9, 2020Results posted

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

A Phase 2 interventional study of Lanraplenib and Filgotinib in Cutaneous Lupus Erythematosus, sponsored by Gilead Sciences. Completed at 16 sites in 2 countries. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-06-09.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 39 studies in Lupus Erythematosus, Cutaneous with a site in United States — 10 open to participants now, 16 under way, 7 of them phase 3. Lupus Erythematosus, Cutaneous · United States.

Enrollment
17th of 34
47 · median 46
Started
2017
the only one that year
Phase 2
15 of 39
1 open now
Registered
16th of 39
by date
Lead sponsor
4 of 39
Gilead Sciences

Among the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, this one is the 17th largest by enrollment of the 34 interventional ones that give a count, is the only one that started in 2017, is one of 15 in phase 2, and was the 16th registered.

Lupus Erythematosus, Cutaneous

67 studies on the registry are indexed under Lupus Erythematosus, Cutaneous; 18 are open to participants now.

Browse Lupus Erythematosus, Cutaneous studies →

Open to participants now

10 of the 39 studies in Lupus Erythematosus, Cutaneous with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Lupus Erythematosus, Cutaneous studies recruiting now, 4 (33%) set no upper age limit and 7 (58%) stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Lupus Erythematosus, Cutaneous with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of filgotinib and lanraplenib (formerly GS-9876) in females with moderately-to-severely active cutaneous lupus erythematosus (CLE).

03

Conditions studied

  • Cutaneous Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have a diagnosis of CLE, either chronic (e.g., discoid) or subacute CLE per investigator evaluation, with the following:

    • Moderately-to-severely active CLE (Cutaneous lupus erythematosus disease area and severity index [CLASI] activity score ≥ 10) at screening and Day 1
    • Prior intolerance or inadequate response to at least one of the listed medications for the treatment of CLE
  • Stable dose (defined as no change in prescription for at least 28 days prior to Day 1) of antimalarials and/or topical or oral is permitted during the study. Individuals who are not planning to continue these medications during the study must have discontinued them at least 28 days prior to Day 1

Key Exclusion Criteria:

  • Use of prohibited concomitant medications per study protocol

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Lanraplenib 30 mg

    Lanraplenib + filgotinib placebo for 48 weeks

    Drug: Lanraplenib · Drug: Filgotinib placebo

  • Experimental
    Filgotinib 200 mg

    Filgotinib + lanraplenib placebo for 48 weeks

    Drug: Filgotinib · Drug: Lanraplenib placebo

  • Placebo comparator
    Placebo

    Filgotinib placebo + lanraplenib placebo for 12 weeks

    Drug: Lanraplenib placebo · Drug: Filgotinib placebo

  • Experimental
    Placebo to Lanraplenib 30 mg

    After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive lanraplenib + filgotinib placebo in a blinded fashion through Week 48.

    Drug: Lanraplenib · Drug: Filgotinib placebo

  • Experimental
    Placebo to Filgotinib 200 mg

    After Week 12 Visit, participants on placebo will be rerandomized 1:1 and receive filgotinib + lanraplenib placebo in a blinded fashion through Week 48.

    Drug: Filgotinib · Drug: Lanraplenib placebo

Interventions

  • 30 mg tablets administered orally once daily with or without food

    Also known as: GS-9876

  • 200 mg tablets administered orally once daily with or without food

    Also known as: GS-6034

  • DrugLanraplenib placebo

    Tablets administered orally once daily with or without food

  • DrugFilgotinib placebo

    Tablets administered orally once daily with or without food

06

What researchers measure

Primary outcomes

  1. Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12

    CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.

    Time frame: Baseline; Week 12

Secondary outcomes

  1. Percentage of Participants at Week 12 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline

    CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.

    Time frame: Baseline; Week 12

  2. Percentage of Participants at Week 12 With No Worsening in CLASI Activity Score From Baseline

    CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease. Worsening was defined as ≥ 3 point increase in CLASI activity score.

    Time frame: Baseline; Week 12

  3. Percentage of Participants at Week 24 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline

    CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.

    Time frame: Baseline; Week 24

  4. Percentage of Participants at Week 24 With No Worsening in CLASI Activity Score From Baseline

    CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease. Worsening was defined as ≥ 3 point increase in CLASI activity score.

    Time frame: Baseline; Week 24

07

Results

Posted Apr 8, 2020

Participant flow

Participants were enrolled at study sites in the United States and Canada. The first participant was screened on 24 May 2017. The last study visit occurred on 18 December 2019.

Treatment Period (Up to Week 12)
Participant flow — Treatment Period (Up to Week 12)
MilestoneLanraplenib 30 mgFilgotinib 200 mgPlaceboPlacebo to Lanraplenib 30 mgPlacebo to Filgotinib 200 mg
Started19181000
Completed1414800
Not completed54200
Withdrew: Adverse event41000
Withdrew: Lost to follow-up11100
Withdrew: Withdrew consent01000
Withdrew: Randomized but not treated01100
Treatment Period (Week 12 to 48)
Participant flow — Treatment Period (Week 12 to 48)
MilestoneLanraplenib 30 mgFilgotinib 200 mgPlaceboPlacebo to Lanraplenib 30 mgPlacebo to Filgotinib 200 mg
Started1414044
Completed1211033
Not completed23011
Withdrew: Withdrew consent02001
Withdrew: Lack of efficacy20000
Withdrew: Investigator's discretion00010
Withdrew: Lost to follow-up01000

Outcome measures

PrimaryChange in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12

CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.

Time frame:
Baseline; Week 12
Reported as:
Least squares mean · score on a scale
Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12
score on a scaleLanraplenib 30 mgFilgotinib 200 mgPlacebo
Change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score From Baseline to Week 12-4.5 ± 1.91-8.7 ± 1.85-5.5 ± 2.56
Statistical analysis
  • Lanraplenib 30 mg vs Placebo · Mixed-effect repeated measures model · p = 0.7500
  • Filgotinib 200 mg vs Placebo · Mixed-effect repeated measures model · p = 0.3047
SecondaryPercentage of Participants at Week 12 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline

CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.

Time frame:
Baseline; Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants at Week 12 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline
Percentage of participantsLanraplenib 30 mgFilgotinib 200 mgPlacebo
Percentage of Participants at Week 12 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline47.4 (24.4 to 71.1)64.7 (38.3 to 85.8)44.4 (13.7 to 78.8)
Statistical analysis
  • Lanraplenib 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.8869
  • Filgotinib 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.3293
SecondaryPercentage of Participants at Week 12 With No Worsening in CLASI Activity Score From Baseline

CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease. Worsening was defined as ≥ 3 point increase in CLASI activity score.

Time frame:
Baseline; Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants at Week 12 With No Worsening in CLASI Activity Score From Baseline
Percentage of participantsLanraplenib 30 mgFilgotinib 200 mgPlacebo
Percentage of Participants at Week 12 With No Worsening in CLASI Activity Score From Baseline84.2 (60.4 to 96.6)94.1 (71.3 to 99.9)88.9 (51.8 to 99.7)
Statistical analysis
  • Lanraplenib 30 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.7456
  • Filgotinib 200 mg vs Placebo · Cochran-Mantel-Haenszel · p = 0.6407
SecondaryPercentage of Participants at Week 24 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline

CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease.

Time frame:
Baseline; Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants at Week 24 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline
Percentage of participantsLanraplenib 30 mgFilgotinib 200 mg
Percentage of Participants at Week 24 With Decrease of ≥ 5 Points in CLASI Activity Score From Baseline50.0 (23.0 to 77.0)83.3 (51.6 to 97.9)
Statistical analysis
  • Lanraplenib 30 mg · One sample exact binomial test · p = <0.0001
  • Filgotinib 200 mg · One sample exact binomial test · p = <0.0001
SecondaryPercentage of Participants at Week 24 With No Worsening in CLASI Activity Score From Baseline

CLASI Activity is scored based on erythema, scale/hyperkeratosis, mucous membrane involvement, acute hair loss and nonscarring alopecia. Evaluation of erythema and scale/hyperkeratosis is based on a table: rows represent anatomical areas and columns represent major clinical symptoms. The extent of involvement for each of the skin symptoms is documented for each anatomic area. The total score ranges from 0-70, with higher scores indicating more severe skin disease. Worsening was defined as ≥ 3 point increase in CLASI activity score.

Time frame:
Baseline; Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants at Week 24 With No Worsening in CLASI Activity Score From Baseline
Percentage of participantsLanraplenib 30 mgFilgotinib 200 mg
Percentage of Participants at Week 24 With No Worsening in CLASI Activity Score From Baseline85.7 (57.2 to 98.2)100.0 (73.5 to 100.0)
Statistical analysis
  • Lanraplenib 30 mg · One sample exact binomial test · p = <0.0001
  • Filgotinib 200 mg · One sample exact binomial test · p = <0.0001

Adverse events

Collected over First dose date up to Week 48 plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lanraplenib 30 mg0/19 (0%)2/19 (10.5%)17/19 (89.5%)
Filgotinib 200 mg0/17 (0%)1/17 (5.9%)11/17 (64.7%)
Placebo0/9 (0%)0/9 (0%)6/9 (66.7%)
Placebo to Lanraplenib 30 mg0/4 (0%)0/4 (0%)3/4 (75%)
Placebo to Filgotinib 200 mg0/4 (0%)0/4 (0%)3/4 (75%)
Most frequent serious events
Most frequent serious events
EventLanraplenib 30 mgFilgotinib 200 mgPlaceboPlacebo to Lanraplenib 30 mgPlacebo to Filgotinib 200 mg
HaemorrhoidsGastrointestinal disorders0/191/170/90/40/4
Coronary artery occlusionCardiac disorders1/190/170/90/40/4
Drug hypersensitivityImmune system disorders1/190/170/90/40/4
Most frequent other events
Showing 10 of 88
Most frequent other events
EventLanraplenib 30 mgFilgotinib 200 mgPlaceboPlacebo to Lanraplenib 30 mgPlacebo to Filgotinib 200 mg
Dry eyeEye disorders0/191/170/91/40/4
Aphthous ulcerGastrointestinal disorders0/190/170/90/41/4
DiarrhoeaGastrointestinal disorders2/191/170/90/41/4
CystitisInfections and infestations0/190/170/90/41/4
NasopharyngitisInfections and infestations1/190/170/91/40/4
Tooth fractureInjury, poisoning and procedural complications0/190/170/91/40/4
MyalgiaMusculoskeletal and connective tissue disorders0/190/170/91/40/4
HeadacheNervous system disorders2/194/170/90/41/4
Skin lesionSkin and subcutaneous tissue disorders0/190/170/91/40/4
HypertensionVascular disorders0/190/170/90/41/4

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Lanraplenib 30 mgFilgotinib 200 mgPlaceboTotal
Mean51 ± 9.043 ± 11.546 ± 7.347 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Lanraplenib 30 mgFilgotinib 200 mgPlaceboTotal
Female1917945
Male0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lanraplenib 30 mgFilgotinib 200 mgPlaceboTotal
American Indian or Alaska Native1001
Asian0022
Black68115
Native Hawaiian or Pacific Islander0000
White127625
Other0202
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lanraplenib 30 mgFilgotinib 200 mgPlaceboTotal
Hispanic or Latino3429
Not Hispanic or Latino1613736
Region of Enrollment
Region of Enrollment(participants)Lanraplenib 30 mgFilgotinib 200 mgPlaceboTotal
Canada4138
United States1516637
Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score
Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) Activity Score(score on a scale)Lanraplenib 30 mgFilgotinib 200 mgPlaceboTotal
Mean17.1 ± 6.1119.7 ± 14.3514.8 ± 4.7917.6 ± 9.89
08

Study locations

16 sites
  • Wallace Rheumatic Studies Center
    Beverly Hills, California 90211, United States
  • St. Jude Hospital Yorba Linda DBA Dr. Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Desert Medical Advances
    Palm Desert, California 92260, United States
  • Medderm Associates
    San Diego, California 92103, United States
  • Inland Rheumatology Clinical Trials
    Upland, California 91786, United States
  • Clinical Research of West Florida, Inc.
    Clearwater, Florida 33765, United States
  • Omega Research Consultants LLC
    DeBary, Florida 32713, United States
  • DJL Clinical Research, PLLC
    Charlotte, North Carolina 28210, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27104, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Dermatology Ottawa Research Centre
    Ottawa, K2C 3N2, Canada
  • University Health Network (UHN) - Toronto Western Hospital
    Toronto, M5T 2S8, Canada
  • K.Papp Clinical Research
    Waterloo, N2J 1C4, Canada
09

References and documents

Publications

  • Werth VP, Fleischmann R, Robern M, Touma Z, Tiamiyu I, Gurtovaya O, Pechonkina A, Mozaffarian A, Downie B, Matzkies F, Wallace D. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022 May 30;61(6):2413-2423. doi: 10.1093/rheumatology/keab685. PubMed 34498056 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Mar 2019, 21 months.

Results were first posted in Apr 2020, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2017
First posted
Apr 28, 2017
StartActual
May 24, 2017
Primary completionActual
Mar 13, 2019
CompletionActual
Dec 18, 2019
Results first posted
Apr 8, 2020
Last update
Jun 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03134222
Lead sponsor
Gilead Sciences
Collaborators
Galapagos NV
Responsible party
Sponsor
First posted
Apr 28, 2017
Start date
May 24, 2017
Primary completion
Mar 13, 2019
Completion
Dec 18, 2019
Results posted
Apr 8, 2020
Last update
Jun 9, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lanraplenib · GLPG0634

Start the discussion